ArticleMucosal immunology2021
Tissue signals imprint Aiolos expression in ILC2s to modulate type 2 immunity.
Article in Mucosal immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- Safety considerations for cereblon-recruiting targeted protein degraders.Nature reviews. Drug discovery · 2026Review
- Heterogeneity and clinical relevance of group 2 innate lymphoid cells subsets in nasal polyps.The Journal of allergy and clinical immunology · 2026Article
- Extracellular Vesicles: A Mailcoach From Mast Cell to Other Cell Species.Immunity, inflammation and disease · 2026Review
- Single-cell analysis reveals an important role of CD137L+ macrophages in the host response to uropathogenic Escherichia coli infection in the bladder.PLoS pathogens · 2025Article
- Spatial mapping of innate lymphoid cells in human lymphoid tissues and lymphoma at single-cell resolution.Nature communications · 2025Article
- Using the Key Characteristics Framework to Unlock the Mysteries of Aryl Hydrocarbon Receptor-Mediated Effects on the Immune System.Annual review of immunology · 2025Review
- Tuft cell IL-17RB restrains IL-25 bioavailability and reveals context-dependent ILC2 hypoproliferation.Nature immunology · 2025Article
- Tissue microenvironment induces tissue specificity of ILC2.Cell death discovery · 2024Review
- Transcriptomic diversity of innate lymphoid cells in human lymph nodes compared to BM and spleen.Communications biology · 2024Article
- Review
- The transcription factor Aiolos restrains the activation of intestinal intraepithelial lymphocytes.Nature immunology · 2024Article
- Transcriptional regulation of innate lymphoid cells and T cells by aryl hydrocarbon receptor.Frontiers in immunology · 2023Review
- Transcription factor-driven regulation of ILC1 and ILC3.Trends in immunology · 2022Review
- Cell-intrinsic view of the aryl hydrocarbon receptor in tumor immunity.Trends in immunology · 2022Review
- Neuropilin-1 mediates lung tissue-specific control of ILC2 function in type 2 immunity.Nature immunology · 2022Article
- Crosstalk between epithelium, myeloid and innate lymphoid cells during gut homeostasis and disease.Frontiers in immunology · 2022Review
- Crosstalk between ILC2s and Th2 CD4Journal of immunology research · 2022Review
- Tissue Resident and Migratory Group 2 Innate Lymphoid Cells.Frontiers in immunology · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Group 2 innate lymphoid cells (ILC2s) manifest tissue heterogeneity and are crucial modulators of regional immune responses. The molecular mechanisms regulating tissue ILC2 properties remain elusive. Here, we interrogate the signatures of ILC2s from five tissues at the transcriptome and epigenetic level. We have found that tissue microenvironment strongly shapes ILC2 identities. The intestine induces Aiolos
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.